A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer

Translational Oncology

Volumn 3, Issue 6, 2010, Pages 373-379

  Ma, Wen Wee ^a   Herman, Joseph M ^a   Jimeno, Antonio ^a   Laheru, Daniel ^a   Messersmith, Wells A ^b   Wolfgang, Christopher L ^a   Cameron, John L ^a   Pawlik, Timothy M ^a   Donehower, Ross C ^a   Rudek, Michelle A ^a   Hidalgo, Manuel ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; ERLOTINIB;

ADJUVANT THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PLASMA; PROSPECTIVE STUDY; RADIATION DOSE; RASH; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA;

EID: 78650311723     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10196     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
2. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, et al. (2008). Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299, 1019-1026.
3. Zuckerman DS and Ryan DP (2008). Adjuvant therapy for pancreatic cancer: a review. Cancer 112, 243-249.
4. Pancreatic adenocarcinoma. NCCN Clinical Practice Guidelines in Oncology (version 1.2008). © 2007 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed October 16, 2008.
5. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, and Verweij J (1998). Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16, 2977-2985.
6. Reigner B, Blesch K, and Weidekamm E (2001). Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40, 85-104.
7. Walko CM and Lindley C (2005). Capecitabine: a review. Clin Ther 27, 23-44.
8. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, and Ishitsuka H (1999). X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5, 2948-2953.
9. Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, and Diasio RB (2007). Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: upregulation of thymidine phosphorylase. Cancer J 13, 247-256.
10. Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, et al. (2005). Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human bxpc-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res 11, 8773-8781.
11. Ma WW and Hidalgo M (2007). Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol 13, 5845-5856.
12. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, and Beger HG (1992). Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J Clin Invest 90, 1352-1360.
13. Bloomston M, Bhardwaj A, Ellison EC, and Frankel WL (2006). Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg 23, 74-79.
14. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25, 1960-1966.
15. Ouchi KF, Yanagisawa M, Sekiguchi F, and Tanaka Y (2006). Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 57, 693-702.
16. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, and Harari PM (2005). Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65, 3328-3335.
17. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, et al. (2001). Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19, 3267-3279.
18. Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, and Hamilton M (2008). The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SIMCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64, 31-41.
19. Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, et al. (2006). Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 24, 656-662.
20. Sharp H, Morris JC, VanWaes C, Gius D, Cooley-Zgela T, and Singh AK (2008). High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. AmJ Clin Oncol 31, 557-560.
21. Wu S (2008). Phase I/II study of concurrent chemo-radiation in combination with erlotinib for locally advanced esophageal carcinoma. J Clin Oncol 26(May 20 suppl). Abstract No. 15670.
22. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, et al. (2008). Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 26, 3503-3510.
23. Xu Y and Grem JL (2003). Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 783, 273-285.
24. Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, and Baker SD (2005). Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23, 3906-3911.
25. Besnard T, Renee N, Etienne-Grimaldi MC, Francois E, and Milano G (2008). Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 870, 117-120.
26. Zhao M, He P, Rudek MA, Hidalgo M, and Baker SD (2003). Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793, 413-420.
27. Gibaldi M and Perrier D (1982). Pharmacokinetics. (2nd ed.). Dekker, New York, NY.
28. D'Argenio DZ and Schumitzky A (1979). A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9, 115-134.
29. Messersmith WA (2005). Phase I trial and biologic study of erlotinib combined with folfox-4 in patients with advanced colorectal cancer: initial results. In ASCO 2005 Gastrointestinal Cancers Symposium. Alexandria, VA: American Society of Clinical Oncology. Abstract No. 260.
30. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, and Lum BL (2006). Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80, 136-145.
31. Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith W, Erlichman C, Pelley R, Jimeno A, Donehower R, Boni J, et al. (2008). A phase I study of ekb-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res 14, 5602-5609.
32. Twelves C, Trigo JM, Jones R,De Rosa F, Rakhit A, Fettner S,Wright T, and Baselga J (2008). Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 44, 419-426.
33. Van Cutsem E, Verslype C, Beale P, Clarke S, Bugat R, Rakhit A, Fettner SH, Brennscheidt U, Feyereislova A, and Delord JP (2008). A phase IB dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol 19, 332-339.
34. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, et al. (2005). Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11, 8105.
35. Neoptolemos JP, Buchler M, Stocken DD, Ghaneh P, Smith D, Bassi C, Moore M, Cunningham D, Dervenis C, and Goldstein D (2009). Espac-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5- fluorouracil/folinic acid (5-fu/fa) versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinoma. J ClinOncol 27(suppl), 18s. Abstract LBA4505.
36. Dunst J, Reese T, Sutter T, Zuhlke H, Hinke A, Kolling-Schlebusch K, and Frings S (2002). Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20, 3983-3991.
37. Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, and Johnson MR (2005). Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23, 8679-8687.
38. Cohen MH, Johnson JR, Chen YF, Sridhara R, and Pazdur R (2005). FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10, 461-466.
39. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353, 123-132.
40. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, et al. (2007). Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25, 4787-4792.
41. Rothenberg ML, Benedetti JK, Macdonald JS, Seay TE, Neubauer MA, George CS, Tanaka MS Jr, Giguere JK, Pruitt BT, and Abbruzzese JL (2002). Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a southwest oncology group study. Ann Oncol 13, 1576-1582.
42. Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, et al. (2003). Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88, 1180-1184.
43. Burris HA III, Rivkin S, Reynolds R, Harris J, Wax A, Gerstein H, Mettinger KL, and Staddon A (2005). Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 10, 183-190.
44. Cereda S and Reni M (2008). Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother 20, 509-512.
45. Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D, Miner T, Martel D, Cioffi W, Remis M, et al. (2005). Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28, 570-575.
46. Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, and O'Reilly EM (2008). A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19, 86-91.